What’s New

Latest News

News
Enfortumab Vedotin Plus Pembrolizumab Maintains Long-Term Survival Benefit in Advanced Urothelial Carcinoma
06/01/2026
Emily Estrada
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the...
06/01/2026
Oncology
Oncology
a strand of RNA
News
SKY-0515 Shows Sustained Biomarker Reductions in Huntington’s Disease
06/01/2026
Maria Mantas
SKY-0515, an investigational oral RNA splicing modifier, reduced mutant huntingtin (mHTT) protein levels in blood by up to 69% and PMS1 mRNA by up to 26% in a phase 1/2 Huntington’s disease (HD) trial. 
SKY-0515, an investigational oral RNA splicing modifier, reduced mutant huntingtin (mHTT) protein levels in blood by up to 69% and PMS1 mRNA by up to 26% in a phase 1/2 Huntington’s disease (HD) trial. 
SKY-0515, an investigational...
06/01/2026
Neurology
Neurology
FDA Approval
FDA Approves Bulevirtide for Hepatitis D Treatment
06/01/2026
Rebecca Mashaw
The approval provides the first FDA-approved treatment option specifically indicated for chronic HDV infection, addressing a substantial unmet medical need in hepatology.
The approval provides the first FDA-approved treatment option specifically indicated for chronic HDV infection, addressing a substantial unmet medical need in hepatology.
The approval provides the first...
06/01/2026
Gastroenterology
Gastroenterology
Behind the Bill
CMS Finalizes Federal IDR Rule to Streamline No Surprises Act Dispute Resolution
05/29/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has finalized updates to the federal Independent Dispute Resolution (IDR) process under the No Surprises Act, lowering administrative fees, creating a centralized dispute portal, and...
The Centers for Medicare & Medicaid Services (CMS) has finalized updates to the federal Independent Dispute Resolution (IDR) process under the No Surprises Act, lowering administrative fees, creating a centralized dispute portal, and...
The Centers for Medicare &...
05/29/2026
First Report Managed Care
First Report Managed Care
News
Bispecific Antibodies Demonstrate Favorable Real-World Outcomes for R/R Follicular Lymphoma
05/29/2026
Rebecca Amrick
Bispecific antibodies demonstrate high efficacy rates and low safety risks when used to treat relapsed or refractory (R/R) follicular lymphoma in real-world settings, indicating their ability to improve patient outcomes.
Bispecific antibodies demonstrate high efficacy rates and low safety risks when used to treat relapsed or refractory (R/R) follicular lymphoma in real-world settings, indicating their ability to improve patient outcomes.
Bispecific antibodies...
05/29/2026
Journal of Clinical Pathways
Journal of Clinical Pathways
a woman scrolls on her phone while laying in bed
News
US Study Finds No Link Between AI Use and Depression
05/28/2026
Maria Mantas
A recent target trial emulation found no evidence of a causal relationship between frequent AI use and increased depressive symptoms among adults.
A recent target trial emulation found no evidence of a causal relationship between frequent AI use and increased depressive symptoms among adults.
A recent target trial emulation...
05/28/2026
Psych Congress Network
Psych Congress Network
News
Busulfan Injections Recalled Due to Failed Impurities/Degradation Specifications
05/28/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class III recall for busulfan injections, 60mg per 10mL (6mg per mL) due to the presence of particulate matter, affecting 9528 vials.
The US Food and Drug Administration (FDA) has issued a Class III recall for busulfan injections, 60mg per 10mL (6mg per mL) due to the presence of particulate matter, affecting 9528 vials.
The US Food and Drug...
05/28/2026
Pharmacy Learning Network
Pharmacy Learning Network

Latest Research

CLD May/June 2026
Cath Lab Digest
Thrombus Burden in ALI and the Role of the Rotarex™ Catheter System
Vol. 34, Issue 3, Issue June 2026

HMP Global Learning Network

Featured Interviews

DLBCL, Diffuse Large B-Cell Lymphoma
Videos
Real-World Survival Impact of CAR T Therapy in Advanced DLBCL: Findings From a SEER Database Analysis: Part 2
05/27/2026
Nishanth Thalambedu, MD
This discussion explores the ongoing barriers to CAR T access and the strategies needed to expand equitable treatment for patients with diffuse large B-cell lymphoma (DLBCL).
This discussion explores the ongoing barriers to CAR T access and the strategies needed to expand equitable treatment for patients with diffuse large B-cell lymphoma (DLBCL).
This discussion explores the...
05/27/2026
Journal of Clinical Pathways
Bruce Sands
Research Review
Bruce Sands, MD, on Results from DUET-CD
05/19/2026
Bruce E. Sands, MD, MS
Dr Sands reviews the results of the DUET-CD study of combination therapy with guselkumab and golimumab in patients with Crohn's disease, which showed a significant increase in efficacy for the combination versus either drug independently.
Dr Sands reviews the results of the DUET-CD study of combination therapy with guselkumab and golimumab in patients with Crohn's disease, which showed a significant increase in efficacy for the combination versus either drug independently.
Dr Sands reviews the results of...
05/19/2026
Advances in Inflammatory Bowel Disease Network
pediatric asthma
Videos
Pediatric Video Tutorial: Pediatric Asthma
05/19/2026
Scott DeBoer, RN, MSN, CPEN, CEN, CCRN, CFRN
Listening for wheezing is good, but asking two simple questions and listening to them talk can be even better.
Listening for wheezing is good, but asking two simple questions and listening to them talk can be even better.
Listening for wheezing is good,...
05/19/2026
EMSWorld
CTP News Desk Image
Viewpoints
Skin Substitute Reimbursement Changes 2026: MAC Denials, Q Codes, and What’s Next
05/19/2026
Daniel L. Kapp, MD
Daniel Kapp, MD, shares his observations on conflicting Medicare contractor guidance and coding confusion in early 2026 have effectively halting reimbursement for skin substitute applications in one MAC. 
Daniel Kapp, MD, shares his observations on conflicting Medicare contractor guidance and coding confusion in early 2026 have effectively halting reimbursement for skin substitute applications in one MAC. 
Daniel Kapp, MD, shares his...
05/19/2026
Wounds
CTP News Desk Image
Viewpoint
Operational Observations in a New CTP Regulatory Environment
05/08/2026
Nikki Johnston; Kati Kaushal, DNP, FNP-C, CWS
Learn more about these consultants' observations in this new regulatory environment.
Learn more about these consultants' observations in this new regulatory environment.
Learn more about these...
05/08/2026
Wounds
Advances in Charcot Neuroarthropathy Surgical Techniques Video
Videos
Advances in Charcot Neuroarthropathy Surgical Techniques Video
05/01/2026
Zeeshan S. Husain, DPM, FACFAS, FASPS; Athanasios Garbis, DPM; Kyle Lawton, DPM
In this video, we highlight emerging reconstruction strategies that move beyond traditional rigid fixation toward a more functional approach to limb preservation.
In this video, we highlight emerging reconstruction strategies that move beyond traditional rigid fixation toward a more functional approach to limb preservation.
In this video, we highlight...
05/01/2026
Podiatry Today
Jonathan Friedberg, MD
Videos
Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine in Advanced Hodgkin Lymphoma
04/30/2026
Jonathan W. Friedberg, MD, MMSc
Jonathan Friedberg, MD, MMSc, discusses results from the SWOG S1826 trial which led to the recent FDA approval of nivolumab plus doxorubicin, vinblastine, and dacarbazine for patients with advanced-stage Hodgkin lymphoma.
Jonathan Friedberg, MD, MMSc, discusses results from the SWOG S1826 trial which led to the recent FDA approval of nivolumab plus doxorubicin, vinblastine, and dacarbazine for patients with advanced-stage Hodgkin lymphoma.
Jonathan Friedberg, MD, MMSc,...
04/30/2026
Oncology
Advanced Squamous Cell Carcinoma of the Anal Canal
Videos
Evaluating Retifanlimab for Advanced Squamous Cell Carcinoma of the Anal Canal in the Frontline Setting
03/31/2026
Lingbin Meng, MD, PhD
Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.
Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.
Lingbin Meng, MD, discusses how...
03/31/2026
First Report Managed Care
Rachid Baz, MD
Videos
BCMA-Targeted Bispecifics and CAR-T in Frontline Multiple Myeloma
03/31/2026
Rachid Baz, MD
Rachid Baz, MD, discusses the emerging role of BCMA-targeted bispecific antibodies and CAR T-cell therapy in transplant-ineligible patients with newly diagnosed multiple myeloma.
Rachid Baz, MD, discusses the emerging role of BCMA-targeted bispecific antibodies and CAR T-cell therapy in transplant-ineligible patients with newly diagnosed multiple myeloma.
Rachid Baz, MD, discusses the...
03/31/2026
Oncology
Al B. Benson, III, MD, FACP, FASCO
Videos
First-Line Immunotherapy in Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC): Evidence Review
03/31/2026
Al B. Benson, III, MD, FACP, FASCO
Dr Benson reviews the epidemiology and unmet clinical need in advanced squamous cell carcinoma of the anal canal (SCAC) and examines the evolving role of immunotherapy in the first-line setting. He also contextualizes recent regulatory and...
Dr Benson reviews the epidemiology and unmet clinical need in advanced squamous cell carcinoma of the anal canal (SCAC) and examines the evolving role of immunotherapy in the first-line setting. He also contextualizes recent regulatory and...
Dr Benson reviews the...
03/31/2026
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use